Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 146, Issue 3, Pages 492-500Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2020.06.036
Keywords
Intravenous immunoglobulin; Fc gamma receptors autoimmunity; inflammation; neonatal Fc receptor
Categories
Funding
- UCB Pharma
- Good Publications Practice (GPP3) guidelines
Ask authors/readers for more resources
Since the first description of the administration of high doses of pooled serum IgG, also referred to as intravenous IgG (IVIg) therapy, as being able to ameliorate various autoimmune diseases, researchers have been investigating which molecular and cellular pathways underlie IVIg activity. Apart from trying to understand the obvious conundrum that IgG can trigger both autoimmune pathology and resolution of inflammation, the rapidly expanding use of IVIg has led to a lack of availability of this primary blood product, providing a strong rationale for developing recombinant alternatives. During the last decade, a tremendous number of novel insights into IVIg activity brought the goal of replacing IVIg within reach, at least in select indications, and has led to the initiation of several clinical trials. At the forefront of this effort is the modulation of autoantibody half-life and blocking access of autoantibodies to fragment cystallizable gamma receptors (Fc gamma receptors). In this rostrum article, we will briefly discuss current models of IVIg activity, followed by a more specific focus on novel therapeutic avenues that are entering the clinic and may replace IVIg in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available